hapabapa/iStock Editorial via Getty Images Novo Nordisk's ( NVO ) obesity therapy Wegovy cut adverse kidney-related events by 22% in obese and overweight individuals in a large placebo-controlled study, according to new data published on Saturday. The analysis was based on the company's SELECT international trial, which tested Wegovy, also known as semaglutide, at a 2.4 mg dose versus placebo as an addition to standard of care in more than 17,000 adults with overweight or obesity.
Professor Helen Colhoun of the University of Edinburgh, the study's lead author, presented the findings on Saturday at the European Renal Congress in Stockholm. "By addressing key markers of kidney health, semaglutide..
.may contribute to a significant reduction in the risk of kidney-related complications, including chronic kidney disease and end-stage renal disease," she said. The Danish drugmaker has well documented the renal benefits of semaglutide in the past.
In March, the company said that the GLP-1 receptor agonist 1.0 mg dose with the standard of care led to a 24% reduction in the risk of kidney disease-related events in patients with type 2 diabetes and chronic kidney disease. Novo’s ( NVO ) rival in the weight loss space, Eli Lilly ( LLY ), which is also testing its obesity drug tirzepatide in kidney-related ailments, traded lower after the announcement.
However, the latest readout "demonstrates for the first time the benefits of semaglutide 2.4 mg in improving kidney function in people w.
